First-line pembrolizumab plus etoposide significantly improved progression-free survival (PFS) and prolonged overall survival (OS) among patients with extensive-stage small cell lung cancer (ES-SCLC) when compared to placebo plus etoposide, according to data presented during an oral presentation at the ASCO 2020 Annual Meeting (Abstract 9001).
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
An abstract is unavailable.
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Answer each quiz question to better understand the patient’s journey and determine the correct diagnosis. Wolters Kluwer (“we” or “us”) wants to inform you about…
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
An abstract is unavailable.
An abstract is unavailable.
An abstract is unavailable.
